"Take out the cash & the company is only valued @ $17M...

"Take out the cash & the company is only valued @ $17M here."

It's actually a great position to be standing in @ $17M with -

Pat-SM6 - multiple melanoma

FDA - Orphan Status
EMA - Orphan status
Phase I/IIa data meeting all end points succesfully
ONYX / AMGEN funding combination trial

Macquarie University using material to develop highly sensitive MM diagnostic test kits < < that's potentially another big kicker with the double hit.

PAT-SM6 - melanoma

Phase I complete


PST-SC1 -

out-license prepped for completed Phase II ovarian cancer


PAT-LM1 -

blood malignancies, solid tumours - lung, pancreas, colon, leukaemias

advanced pre-clinical & set to enter clinic 2014 ?

PAT-SM3 / PAT-NM1 -

preclinical



Find me another company that beats it at $27M with $10M CiB